GlassScriptPhysician profile
Shreya Gor
NPI 1992238075
$6,553.80
in general payments reported to CMS, 2019-2025
23 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $911 · 2023: $1,937 · 2024: $1,765 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,642.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,470.59 | 2022-2025 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $1,045.79 | 2022-2025 | |
| Ucb, INC. | $829.82 | 2022-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $643.21 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $466.65 | 2022-2025 | |
| Genzyme Corporation | $363.16 | 2024-2025 | |
| Glaxosmithkline, LLC. | $241.14 | 2023-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $234.45 | 2022-2024 | Saphnelo |
| Lilly USA, LLC | $229.45 | 2022-2025 | Taltz |
| Radius Health, INC. | $154.12 | 2023-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $142.30 | 2022-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $104.80 | 2023-2025 | Strensiq |
| Genentech USA, INC. | $101.56 | 2023-2025 | Actemra, Gazyva |
| Sandoz INC. | $101.53 | 2023-2025 | Hyrimoz, Jubbonti |
| Sobi, INC | $78.44 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.60 | 2023-2024 | Cyltezo |
| Scilex Pharmaceuticals INC. | $69.00 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $47.08 | 2023 | Arcalyst |
| Alvogen INC | $43.84 | 2024 | Teriparatide |
| Horizon Therapeutics Plc | $39.20 | 2023 | Krystexxa |
| Fidia Pharma USA INC. | $29.11 | 2024-2025 | Triluron, Hymovis, Hyalgan |
| Qiagen, LLC | $28.77 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.19 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shreya Gor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.